Phase II Study of Erlotinib (Tarceva) in Patients With Advanced Pancreatic Adenocarcinoma.
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Erlotinib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 29 Sep 2010 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 29 Sep 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.